Please assess the completion status of the following clinical trial:

Trial Title: Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with advanced (unresectable, recurrent or metastatic) RCC~* Patients reasonably likely to benefit from treatment with sorafenib as a single agent therapy~* Patients with an ECOG performance status of 0-2~* Patients who will not require other systemic anticancer therapy (except for bisphosphonates) while taking sorafenib~* Patients with vascular diseases such as wet macular degeneration, vasculitis, or new peptic ulcer, may be enrolled but require close monitoring in accordance with established medical practice~Exclusion Criteria:~* Patients who are currently enrolled in, are eligible for, or have access to, any other sorafenib clinical trial~* Patients who have participated in any other sorafenib trial~* Patients who have had prior therapy with investigational agent(s) within the last four weeks prior to study entry~* Life expectancy of less than two months~* Patients with cardiac arrhythmias greater than grade 1 NCI CTCAE, Version 3.0~* Patients with active coronary artery disease or ischemia~* Patients with Child-Pugh class C hepatic impairment~* Patients with severe renal impairment or who require dialysis~* Patients with active uncontrolled hypertension~* Patients with recent or active bleeding diathesis

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).